Sagar Lonial, MD, FACP, chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, sat down with Targeted Oncology to discuss the role of anti-BCMA therapies. He discussed how bispecific t cell engagers play a role in myeloma.

To read the full transcript, visit Targeted Oncology.

Tags: myeloma, bispecific t cell engagers, BCMA